Williams MD et al., 2004-10-01: Analysis of 1999 hospital discharges in six states projected nationally. Severe sepsis was present in 4.9% of cancer hospitalisations, carried 37.8% in-hospital mortality, and was associated with 8.5% of all cancer deaths.
Overall, severe sepsis is associated with 8.5% (46,729) of all cancer deaths at a cost of 3.4 billion dollars per year.
Abstract (Results)
Williams MD et al., 2004-10-01: Analysis of 1999 hospital discharges in six states projected nationally. Severe sepsis was present in 4.9% of cancer hospitalisations, carried 37.8% in-hospital mortality, and was associated with 8.5% of all cancer deaths. CONFLICT OF INTEREST IS MATERIAL: all authors were at Lilly Research Laboratories, Eli Lilly & Company, maker of drotrecogin alfa (Xigris), the sepsis drug of that era; the study is a Lilly-authored database analysis. Comparator: cancer patients with severe sepsis vs other hospitalisations and vs the general population (RR 3.96 for severe sepsis hospitalisation). The 8.5% figure supports 'nearly 10 percent of cancer-related deaths' but applies to ALL cancer patients, not to chemotherapy recipients, and it is severe sepsis, not infection generally.
